Pituitary Preceptorship: How do I decide when to discontinue cabergoline therapy in prolactinomas
Pituitary Preceptorship: How do I decide when to discontinue cabergoline therapy in prolactinomas
Dr. Greisa Vila
The educational content presented and discussed during the meeting are now available.Dr. Greisa Vila
Endocrinologist
Medical University of Vienna
Austria
Dr. Greisa Vila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 15 min |accreditation: EACCME | Nov 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme is supported by an Independent Educational Grant from Ipsen
PITUITARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen.